Company intelligence / Profile preview

FineHeart

Ownership: Private
Development stage: Phase 1

Overview

FineHeart has developed the FlowMaker®, a fully implantable left ventricular assist device designed to work in synergy with the heart’s natural contraction. The company received authorization in June 2025 to begin its First-In-Human clinical trial in France after initial successful implantations in Prague. Early results presented at international congresses indicate promising safety and feasibility for patients with advanced heart failure, aiming for less invasive intervention and preservation of native cardiac function compared to current devices.

Therapeutic areas: Cardiovascular
Modalities: DeviceImplantable device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

ICOMS FlowMaker

Phase 1

Indications: Advanced heart failure

Partnerships

Likely collaborations with French cardiac surgery centersIKEM Prague for clinical studies

Beyond the preview

Go deeper on FineHeart.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FineHeart.

Explore the full profile